Trial
NCT00015847
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
OHSU Knight Cancer Institute
Collaborators
National Cancer Institute (NCI)
Condition
Leukemia
Intervention
recombinant interferon alfa
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-22